Novartis's Sandoz Enters Commercialization Agreement for Oncology Medicine
08 Setembro 2021 - 9:21AM
Dow Jones News
By Giulia Petroni
Novartis AG said Wednesday that its generics division Sandoz has
entered into a commercialization agreement with biopharmaceutical
company Bio-Thera Solutions, Ltd. for oncology medicine biosimilar
bevacizumab.
The Swiss pharmaceutical company said it will have the right to
commercialize the medicine upon approval in the U.S., Europe
excluding Russia, and Canada among other countries, while Bio-Thera
Solutions will be in charge of development and manufacturing.
Bevacizumab is used for the treatment of multiple types of
cancer.
Under the agreement, Bio-Thera Solutions will receive upfront
and milestone payments and will also be entitled to receive profit
share payments in the partnered territory, Novartis said.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
September 08, 2021 08:06 ET (12:06 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024